The University of Southampton
University of Southampton Institutional Repository

Single centre evaluation of the impact of respiratory metagenomics on clinical outcomes and antimicrobial prescribing in the management of severe pneumonia in the intensive care units (ICUs)

Single centre evaluation of the impact of respiratory metagenomics on clinical outcomes and antimicrobial prescribing in the management of severe pneumonia in the intensive care units (ICUs)
Single centre evaluation of the impact of respiratory metagenomics on clinical outcomes and antimicrobial prescribing in the management of severe pneumonia in the intensive care units (ICUs)
Introduction: severe pneumonia (SP) is a leading cause of ICU admission and remains associated with high morbidity and mortality despite established antimicrobial (AM) therapy and best supportive care [1]. Metagenomic next-generation sequencing (mNGS)enables direct DNA sequencing of clinical samples, providing rapid pathogen identification with potential to optimise antimicrobial prescribing (AM) on the same day [2]. Sepsis research priorities and UK Health policy highlight the need for rapid accurate diagnostics to contain antimicrobial resistance and improve antimicrobial stewardship [3].

Objectives: to determine whether the introduction of respiratory mNGS was associated with improved antimicrobial (AM) optimisation and clinical outcomes in critically-ill patients with suspected SP.

Methods: we conducted a single-centre retrospective cohort study of ICU patients with suspected SP between November 2024 and March 2025. Ethics approval was obtained (CRIT-CO Study, IRAS 232922; UHS local governance registration SEV/0860). Patients were stratified by mNGS result outcome, with technical failures used as control. For patients with multiple tests, only the first diagnostic result was analysed. Propensity score matching (1:1, nearest neighbour, age and APACHE II) produced two comparable groups. Clinical demographic data were obtained from clinical information systems. WHO AWaRe classification and defined daily doses (DDDs) were used to standardise the data for comparison.

Results: a total of 138 patients underwent mNGS testing, 30 experienced a technical failure, commonly due to internal control failure. Two matched cohort groups of 25patients were analysed with similar demographics: mean age 66 ±13 vs. 64 ±12years; mean APACHE II scores 19 ±6 vs. 17 ±7; and 68% vs. 52% males in them NGS and control groups respectively. On sampling day, 20/25 (80%) (mNGS) and 21/25 (84%) (control) received a mean(SD) of 2.0 (±1.4) and 1.9 (±0.8) AMs respectively. In the mNGS cohort, at days 3and 7, 17/20 (85%) and 9/14 (64%) respectively, of remaining patients received AMs, compared to 13/19 (68%) and 7/9 (78%) in control group (Figure1). Cumulative antibacterial consumption 7 days post sampling, (DDDs) was 174.5in the mNGS group and 184.2 in control. There was higher use of reserve category antibiotics in the mNGS group in the 7 days post sampling (Figure 2). Antifungal use at day 7 was numerically higher in the control group 3/9 (33%) vs. 2/14(14%). (Figure 3).ICU and hospital length of stay were similar in both cohorts: median 9 (4-12) and23 (15-31) days in the mNGS and 6 (3-10) and 23 (9-42) days in the control groups respectively.

Conclusions: in this small retrospective matched cohort study, the introduction of mNGS was associated with modest reductions of overall AM consumption but increased use of reserve antibiotics. An interesting finding was increased antifungal exposure in the control group later in the ICU stay. Clinical outcomes, ICU and hospital length of stay, were comparable. The study is limited by small sample size, retrospective design and single- centre setting. Ongoing and future work from this mNGS programme will further assess the impact of mNGS on antimicrobial stewardship and patient outcomes in SP.
2197-425X
Swabe, Jacqueline
7182574f-976e-46d6-802b-7f9e94b31ba1
Young, David
ac65da82-e719-4879-9aeb-5c669084e70c
Saeed, Kordo
87cb67e5-71e8-4759-bf23-2ea00ebd8b39
Edgeworth, Jonathan
987b8cef-cd42-4b69-8f00-a2a631d92687
Dushianthan, Ahilanandan
013692a2-cf26-4278-80bd-9d8fcdb17751
Snell, Luke
629c0126-424c-43aa-8533-34d3a15b03d8
Ibrahim, Mukhtar
d4d7ede3-451b-4ffe-b9c6-1f0e35f4282b
Mckenzie, Cathrine
13ad9cca-fa4f-451b-a3f4-5c83d1ef3b8c
Swabe, Jacqueline
7182574f-976e-46d6-802b-7f9e94b31ba1
Young, David
ac65da82-e719-4879-9aeb-5c669084e70c
Saeed, Kordo
87cb67e5-71e8-4759-bf23-2ea00ebd8b39
Edgeworth, Jonathan
987b8cef-cd42-4b69-8f00-a2a631d92687
Dushianthan, Ahilanandan
013692a2-cf26-4278-80bd-9d8fcdb17751
Snell, Luke
629c0126-424c-43aa-8533-34d3a15b03d8
Ibrahim, Mukhtar
d4d7ede3-451b-4ffe-b9c6-1f0e35f4282b
Mckenzie, Cathrine
13ad9cca-fa4f-451b-a3f4-5c83d1ef3b8c

Swabe, Jacqueline, Young, David, Saeed, Kordo, Edgeworth, Jonathan, Dushianthan, Ahilanandan, Snell, Luke, Ibrahim, Mukhtar and Mckenzie, Cathrine (2026) Single centre evaluation of the impact of respiratory metagenomics on clinical outcomes and antimicrobial prescribing in the management of severe pneumonia in the intensive care units (ICUs). Intensive care medicine experimental. (Submitted)

Record type: Meeting abstract

Abstract

Introduction: severe pneumonia (SP) is a leading cause of ICU admission and remains associated with high morbidity and mortality despite established antimicrobial (AM) therapy and best supportive care [1]. Metagenomic next-generation sequencing (mNGS)enables direct DNA sequencing of clinical samples, providing rapid pathogen identification with potential to optimise antimicrobial prescribing (AM) on the same day [2]. Sepsis research priorities and UK Health policy highlight the need for rapid accurate diagnostics to contain antimicrobial resistance and improve antimicrobial stewardship [3].

Objectives: to determine whether the introduction of respiratory mNGS was associated with improved antimicrobial (AM) optimisation and clinical outcomes in critically-ill patients with suspected SP.

Methods: we conducted a single-centre retrospective cohort study of ICU patients with suspected SP between November 2024 and March 2025. Ethics approval was obtained (CRIT-CO Study, IRAS 232922; UHS local governance registration SEV/0860). Patients were stratified by mNGS result outcome, with technical failures used as control. For patients with multiple tests, only the first diagnostic result was analysed. Propensity score matching (1:1, nearest neighbour, age and APACHE II) produced two comparable groups. Clinical demographic data were obtained from clinical information systems. WHO AWaRe classification and defined daily doses (DDDs) were used to standardise the data for comparison.

Results: a total of 138 patients underwent mNGS testing, 30 experienced a technical failure, commonly due to internal control failure. Two matched cohort groups of 25patients were analysed with similar demographics: mean age 66 ±13 vs. 64 ±12years; mean APACHE II scores 19 ±6 vs. 17 ±7; and 68% vs. 52% males in them NGS and control groups respectively. On sampling day, 20/25 (80%) (mNGS) and 21/25 (84%) (control) received a mean(SD) of 2.0 (±1.4) and 1.9 (±0.8) AMs respectively. In the mNGS cohort, at days 3and 7, 17/20 (85%) and 9/14 (64%) respectively, of remaining patients received AMs, compared to 13/19 (68%) and 7/9 (78%) in control group (Figure1). Cumulative antibacterial consumption 7 days post sampling, (DDDs) was 174.5in the mNGS group and 184.2 in control. There was higher use of reserve category antibiotics in the mNGS group in the 7 days post sampling (Figure 2). Antifungal use at day 7 was numerically higher in the control group 3/9 (33%) vs. 2/14(14%). (Figure 3).ICU and hospital length of stay were similar in both cohorts: median 9 (4-12) and23 (15-31) days in the mNGS and 6 (3-10) and 23 (9-42) days in the control groups respectively.

Conclusions: in this small retrospective matched cohort study, the introduction of mNGS was associated with modest reductions of overall AM consumption but increased use of reserve antibiotics. An interesting finding was increased antifungal exposure in the control group later in the ICU stay. Clinical outcomes, ICU and hospital length of stay, were comparable. The study is limited by small sample size, retrospective design and single- centre setting. Ongoing and future work from this mNGS programme will further assess the impact of mNGS on antimicrobial stewardship and patient outcomes in SP.

Text
LIVES2026 - Author's Original
Restricted to Repository staff only
Request a copy

More information

Submitted date: 15 April 2026
Venue - Dates: European Society of Intensive Care Medicine : LIVES2026, LISBON, LISBON, Portugal, 2026-10-10 - 2026-10-15

Identifiers

Local EPrints ID: 511883
URI: https://eprints.soton.ac.uk/id/eprint/511883
ISSN: 2197-425X
PURE UUID: 543ace29-6fe2-4a10-8994-6145fd65efbc
ORCID for Kordo Saeed: ORCID iD orcid.org/0000-0003-0123-0302
ORCID for Ahilanandan Dushianthan: ORCID iD orcid.org/0000-0002-0165-3359
ORCID for Cathrine Mckenzie: ORCID iD orcid.org/0000-0002-5190-9711

Catalogue record

Date deposited: 09 Jun 2026 16:42
Last modified: 13 Sep 2026 15:48

Export record

Contributors

Author: Jacqueline Swabe
Author: David Young
Author: Kordo Saeed ORCID iD
Author: Jonathan Edgeworth
Author: Ahilanandan Dushianthan ORCID iD
Author: Luke Snell
Author: Mukhtar Ibrahim
Author: Cathrine Mckenzie ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×